| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNEN/60.2.161 |
| P698 | PubMed publication ID | 11273004 |
| P50 | author | Pradeep G Bhide | Q37372271 |
| P2093 | author name string | Uchiyama Y | |
| Aronin N | |||
| DiFiglia M | |||
| Sapp E | |||
| Vonsattel JP | |||
| Tohyama K | |||
| Hashikawa T | |||
| Kegel KB | |||
| P2860 | cites work | Extensive and long-lasting changes of glial cells following transection of the postcommissural fornix in the adult rat. | Q48181355 |
| Expression of thymosin beta4 messenger RNA in normal and kainate-treated rat forebrain | Q48203853 | ||
| Microglial and astrocytic cell responses in the rat hippocampus after an intracerebroventricular kainic acid injection | Q48281139 | ||
| Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease | Q48373983 | ||
| Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. | Q48463886 | ||
| Huntington disease. | Q48465200 | ||
| Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. | Q48480334 | ||
| The CNS acute inflammatory response to excitotoxic neuronal cell death. | Q48648473 | ||
| Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease. | Q53214536 | ||
| Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. | Q53338394 | ||
| Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons | Q24317574 | ||
| Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells | Q24561696 | ||
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Thymosin beta 4 binds actin in an extended conformation and contacts both the barbed and pointed ends | Q28238396 | ||
| Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation | Q28246858 | ||
| Huntingtin interacts with a family of WW domain proteins | Q28279245 | ||
| Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes | Q28910318 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| Microglia: a sensor for pathological events in the CNS | Q29620556 | ||
| Proteasome inhibitors: valuable new tools for cell biologists | Q29620573 | ||
| Developmental expression of mRNAs encoding thymosins beta 4 and beta 10 in rat brain and other tissues | Q33507918 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease | Q34168124 | ||
| Identification and characterization of mRNAs regulated by nerve growth factor in PC12 cells | Q36472638 | ||
| Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. | Q36774484 | ||
| Complement activation by beta-amyloid in Alzheimer disease | Q37262889 | ||
| Expression of thymosin beta 4 gene during Xenopus laevis embryogenesis | Q38329321 | ||
| Risk of Alzheimer's disease and duration of NSAID use. | Q39457609 | ||
| Mapping the binding site of thymosin beta4 on actin by competition with G-actin binding proteins indicates negative co-operativity between binding sites located on opposite subdomains of actin | Q41833004 | ||
| Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus | Q43814253 | ||
| The cortical neuritic pathology of Huntington's disease | Q45288549 | ||
| Morphometric analysis of the prefrontal cortex in Huntington's disease | Q45293165 | ||
| Huntingtin localization in brains of normal and Huntington's disease patients | Q45295341 | ||
| Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease | Q45295751 | ||
| Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease | Q45297318 | ||
| Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis | Q45307235 | ||
| Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis | Q46076651 | ||
| Localization of thymosin beta 4 to the neural tissues during the development of Xenopus laevis, as studied by in situ hybridization and immunohistochemistry | Q48105209 | ||
| P433 | issue | 2 | |
| P921 | main subject | Huntington's disease | Q190564 |
| microglia | Q1622829 | ||
| P304 | page(s) | 161-172 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Journal of Neuropathology & Experimental Neurology | Q15716771 |
| P1476 | title | Early and progressive accumulation of reactive microglia in the Huntington disease brain | |
| P478 | volume | 60 |
| Q52721984 | A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. |
| Q27933811 | A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease |
| Q40659365 | A method to improve selection of molecular targets by circumventing the ADME pharmacokinetic system utilizing PharmArray DNA microarrays |
| Q34795840 | A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease |
| Q37345118 | A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease |
| Q27334472 | AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease |
| Q33985904 | Abnormal peripheral chemokine profile in Huntington's disease |
| Q42488000 | Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. |
| Q35103285 | Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons |
| Q35172268 | Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. |
| Q35067317 | Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNy but not to TGFβ1 or M-CSF. |
| Q38974741 | Age-Dependent Changes in the Activation and Regulation of Microglia. |
| Q90003697 | Ageing as a risk factor for neurodegenerative disease |
| Q47138180 | Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum |
| Q46212807 | An adaptive role of TNFα in the regulation of striatal synapses |
| Q30480013 | Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood |
| Q38016572 | Androgen function in the pathophysiology and treatment of male Huntington's disease patients |
| Q42319141 | BMP signaling through BMPRIA in astrocytes is essential for proper cerebral angiogenesis and formation of the blood-brain-barrier |
| Q57405353 | Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases |
| Q43257486 | Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease |
| Q36608360 | Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease |
| Q37113861 | Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease |
| Q36615488 | CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. |
| Q36416377 | Cannabinoid CB2 receptors in human brain inflammation |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q36977766 | Cannabinoids and neuroprotection in basal ganglia disorders. |
| Q90140618 | Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models |
| Q28510296 | Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice |
| Q36140894 | Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease |
| Q38257697 | Challenges of Huntington's disease and quest for therapeutic biomarkers. |
| Q28085041 | Changing the face of kynurenines and neurotoxicity: therapeutic considerations |
| Q37926912 | Cholesterol metabolism in Huntington disease |
| Q33873289 | Contributions of microglia to structural synaptic plasticity |
| Q38015354 | Current understanding of the glial response to disorders of the aging CNS. |
| Q35867007 | Deficits in Sustained Attention and Changes in Dopaminergic Protein Levels following Exposure to Proton Radiation Are Related to Basal Dopaminergic Function |
| Q39037984 | Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease |
| Q45292699 | Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease |
| Q36950670 | Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in a Drosophila model of expanded repeat neurodegenerative diseases. |
| Q28578346 | Distribution and expression of tissue inhibitors of metalloproteinase in dorsal root entry zone and dorsal column after dorsal root injury |
| Q27498993 | Does neuroinflammation fan the flame in neurodegenerative diseases? |
| Q44598083 | Dose-dependent effect of MK-801 on the levels of neuropeptides processing enzymes in rat brain regions |
| Q37040974 | Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease |
| Q37580232 | Early defect of transforming growth factor β1 formation in Huntington's disease. |
| Q28472880 | Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice |
| Q36626877 | Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease |
| Q35752429 | Experimental therapeutics in transgenic mouse models of Huntington's disease |
| Q36320596 | Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity |
| Q45305307 | Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease |
| Q41873152 | Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease |
| Q40717328 | Fractalkine and fractalkine receptors in human neurons and glial cells |
| Q37456579 | Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. |
| Q36381405 | Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease |
| Q36338269 | Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q24621854 | Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease |
| Q37697482 | HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation |
| Q27323092 | High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model |
| Q45307207 | Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. |
| Q28281434 | Huntingtin and its role in neuronal degeneration |
| Q38267443 | Huntington's Disease: An Immune Perspective. |
| Q39035495 | Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies |
| Q38663090 | Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets. |
| Q33773061 | Huntington's disease: from molecular pathogenesis to clinical treatment |
| Q57178431 | Huntington's disease: the coming of age |
| Q36128464 | Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality |
| Q44728742 | Imaging of glia activation in people with primary lateral sclerosis. |
| Q38015834 | Imaging of microglia in patients with neurodegenerative disorders |
| Q90248470 | Immunotherapies in Huntington's disease and α-Synucleinopathies |
| Q35974720 | In vivo dynamics of retinal microglial activation during neurodegeneration: confocal ophthalmoscopic imaging and cell morphometry in mouse glaucoma |
| Q45289337 | Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. |
| Q38884155 | Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity |
| Q48771635 | Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction. |
| Q47786283 | Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons. |
| Q60916597 | Insights into GABAergic system alteration in Huntington's disease |
| Q37992251 | Intercellular (mis)communication in neurodegenerative disease. |
| Q92633176 | Interleukin-1 Beta Neutralization Attenuates Traumatic Brain Injury-Induced Microglia Activation and Neuronal Changes in the Globus Pallidus |
| Q92816537 | Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease |
| Q63977060 | Invited Lectures : Overviews Purinergic signalling: past, present and future |
| Q37892975 | Involvement of kynurenines in Huntington's disease and stroke-induced brain damage |
| Q37410973 | JAK/STAT Signalling in Huntington's Disease Immune Cells. |
| Q39375357 | KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients |
| Q36599891 | Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced Huntington's-Like Symptoms |
| Q26782867 | Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology |
| Q58546864 | Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease |
| Q37169655 | Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells |
| Q27316866 | Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. |
| Q37060394 | M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia |
| Q33112256 | Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease |
| Q24647617 | Methamphetamine toxicity and messengers of death |
| Q45289720 | Microglia density decreases with age in a mouse model of Huntington's disease. |
| Q91786444 | Microglia in neurodegeneration |
| Q91780157 | Microglia roles in synaptic plasticity and myelination in homeostatic conditions and neurodevelopmental disorders |
| Q29547835 | Microglia-mediated neurotoxicity: uncovering the molecular mechanisms |
| Q33809556 | Microglial Activation in the Pathogenesis of Huntington's Disease |
| Q92882814 | Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease |
| Q40660071 | Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies |
| Q43469689 | Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study |
| Q38203788 | Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity |
| Q33529862 | Microglial responses around intrinsic CNS neurons are correlated with axonal regeneration |
| Q21710687 | Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders |
| Q29248766 | Molecular Imaging Markers to Track Huntington’s Disease Pathology |
| Q37629256 | Molecular bases of methamphetamine-induced neurodegeneration |
| Q45293567 | Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice |
| Q36686156 | Multiple pathways contribute to the pathogenesis of Huntington disease |
| Q33959395 | Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors |
| Q30530945 | Mutant huntingtin impairs immune cell migration in Huntington disease. |
| Q33796172 | Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice |
| Q45305061 | Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications |
| Q35558052 | Neurodegeneration severity can be predicted from early microglia alterations monitored in vivo in a mouse model of chronic glaucoma |
| Q58737028 | Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches |
| Q35572092 | Neurodegenerative processes in Huntington's disease |
| Q30834004 | Neuroimaging in Huntington's disease |
| Q28072237 | Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies |
| Q37763886 | Neuroinflammation in Huntington's disease |
| Q39173756 | Neuroinflammation in Neurodegenerative Disorders-a Review |
| Q28186120 | Neuron-specific distribution of P2X7 purinergic receptors in the monkey retina |
| Q37761852 | Neurotoxic protein oligomerisation associated with polyglutamine diseases |
| Q36797987 | Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms |
| Q37642283 | Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond |
| Q57187524 | Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease |
| Q37460122 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease |
| Q38673408 | PET Imaging in Huntington's Disease |
| Q37212391 | Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism |
| Q33614987 | Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease |
| Q38094970 | Peripheral inflammation in neurodegeneration. |
| Q35550999 | Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation |
| Q45299602 | Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease |
| Q37709833 | Polyglutamine toxicity in non-neuronal cells |
| Q36864320 | Positron emission tomography imaging of neuroinflammation |
| Q34392509 | Protection by glia-conditioned medium in a cell model of Huntington disease |
| Q36461072 | Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease |
| Q33310422 | Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation |
| Q51758698 | Reactive Neuroblastosis in Huntington's Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain. |
| Q36376140 | Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration |
| Q97066909 | Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington's Disease |
| Q64898638 | Regional differences in dopamine release in the R6/2 mouse caudate putamen. |
| Q39004244 | Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target |
| Q24563024 | Role of microglia in central nervous system infections |
| Q26863534 | Role of prostaglandins in neuroinflammatory and neurodegenerative diseases |
| Q34510347 | STAT1 mediates oroxylin a inhibition of iNOS and pro-inflammatory cytokines expression in microglial BV-2 cells |
| Q37326825 | Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model |
| Q45306451 | Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. |
| Q37296047 | Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. |
| Q33730187 | Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington´s disease |
| Q92851797 | Striatal Projection Neurons Require Huntingtin for Synaptic Connectivity and Survival |
| Q34998578 | Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice |
| Q38397575 | Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases |
| Q47933053 | Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17. |
| Q88960978 | TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31 |
| Q45306608 | Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats |
| Q26764930 | The P42 peptide and Peptide-based therapies for Huntington's disease |
| Q35185575 | The beta-thymosins, small actin-binding peptides widely expressed in the developing and adult cerebellum. |
| Q37969749 | The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology |
| Q26828403 | The choreography of neuroinflammation in Huntington's disease |
| Q36370547 | The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q61772849 | The identity and function of microglia in neurodegeneration |
| Q38223504 | The role of dopamine in Huntington's disease |
| Q37868923 | The role of immunity in Huntington's disease |
| Q34038205 | The role of microglia in human disease: therapeutic tool or target? |
| Q35271805 | The role of the immune system in triplet repeat expansion diseases |
| Q36462035 | The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction |
| Q28391948 | The ubiquitin proteasome system in glia and its role in neurodegenerative diseases |
| Q38544332 | The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach. |
| Q64859904 | Therapeutic approaches to Huntington disease: from the bench to the clinic |
| Q34007803 | Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke |
| Q35135176 | Thymosin beta4: a candidate for treatment of stroke? |
| Q33888545 | Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway |
| Q26849677 | Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy |
| Q34064518 | Transgenic rat model of Huntington's disease: a histopathological study and correlations with neurodegenerative process in the brain of HD patients. |
| Q33624586 | Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases |
| Q34043950 | Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease |
| Q45296591 | Tryptophan metabolism and oxidative stress in patients with Huntington's disease |
| Q35038274 | Unfolding the role of protein misfolding in neurodegenerative diseases |
| Q100559962 | Wild-type huntingtin regulates human macrophage function |
| Q39065494 | X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B. |
Search more.